Navigation Links
Study Finds Moderate Hypothermia A Safe Treatment For Traumatic Brain Injury In Kids

A first-of-its-kind multi-center trial has shown that cooling the body can have positive affects on children who suffered traumatic brain injury.

The study's lead investigator, Children's Hospital of Pittsburgh neurosurgeon P. David Adelson, MD, and fellow researchers determined that induced moderate hypothermia initiated after severe traumatic brain injury (TBI) is a safe therapeutic intervention for children.

TBI initiates several metabolic processes that can exacerbate the injury. Adult research has produced evidence that hypothermia may limit some of these deleterious metabolic responses.

The trial, which is the only multi-center clinical trial involving children underway in the United States, was conducted to determine whether moderate hypothermia (32-33 degrees Celsius) begun in the early period after severe TBI and maintained for 48 hours is safe compared with normal body temperature (36.5-37.5 degrees Celsius). By inducing hypothermia in pediatric patients down to 32 degrees Celsius, doctors found that hypothermia tended to reduce mortality, lower the severity of intracranial hypertension during the cooling phase and has the potential to improve the functional outcome of young patients.

Therefore, it was determined that hypothermia is likely a safe therapeutic intervention for children after severe TBI up to 24 hours after injury

Study results are published in the April issue of the journal, Neurosurgery. A total of 75 patients were involved in the trial, which was funded by the National Institutes of Health.

"Traumatic brain injury causes more children's deaths in this country than all other causes of death combined," said Dr. Adelson, who is the director of the Pediatric Neurotrauma Center at Children's Hospital of Pittsburgh. "There is no one thing that can effectively treat all cases of traumatic brain injury, but our hope is that with the cooling from hypothermia, we may block or slow down the brain's delet erious biochemical mechanisms following an injury and also be able to develop other more effective treatments."

Lowering body temperature can help control brain swelling and intracranial pressure, which can also exacerbate secondary injury if left unchecked. Induced hypothermia can be accomplished using several methods. Surface cooling methods such as cooling blankets placed under and on top of patients and ice packs placed in the groin and armpit areas are effective in decreasing temperature.

In addition to safety, mortality and complications during the treatment protocol and during hospitalization, the study also assessed functional and cognitive outcome in these children with severe traumatic brain injury.

After severe TBI, 48 children less than 13 years of age admitted within six hours of injury were randomized by age to moderate hypothermia treatment in conjunction with standardized head injury management versus normal body temperature.

An additional 27 patients were entered into a parallel trial of those patients who were excluded because there was a delay in transfer of greater than six hours following injury but within 24 hours of admission, or unknown time when the injury occurred (i.e. child abuse) or were an adolescent (13-18 years old).

Assessments of safety included mortality, infection, coagulopathy (blood clotting), arrhythmias and hemorrhage as well as ability to maintain target temperature, mean intracranial pressure (ICP), and percent time of ICP less than 20 mm Hg during the cooling and subsequent rewarming phases. Additionally, assessments of neurocognitive outcomes were obtained at three and six months of follow-up. Researchers will conduct further studies to determine the effect of moderate hypothermia on functional outcome and intracranial hypertension.


'"/>

Source:Children's Hospital of Pittsburgh


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... ... 22, 2017 , ... AESKU.GROUP, an innovation leader in ... Technologien GmbH, thereby expanding its product portfolio to include allergy and food intolerance ... atopic eczema or a food allergy. Allergies are escalating to epidemic proportions and ...
(Date:6/22/2017)... ... 2017 , ... RURO, Inc., a leading LIMS, RFID, and ... update to the Limfinity® framework. , LimitLIS® and other RURO solutions based on ... customers among labs and other businesses. Limfinity® 6.5 adds new features and improvements ...
(Date:6/20/2017)... Pa. , June 20, 2017  Kibow Biotech ... pleased to announce the issuance of a new patent ... or hyperuricemia by the U.S. Patent and Trademark Office ... a winner of the Buzz of Bio award in ... is akin to developing non-drug approaches to chronic disease. ...
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... ... solutions for clinical development reported today that it is launching two new additions ... company will be demonstrating new capabilities at the DIA 2017 Annual Meeting in ...
Breaking Biology Technology: